'Stone gw et al' diaporamas de présentation

Drug Eluting Stents overhyped, overused and overpriced?

Advanced Angioplasty 2008 BCIS 23 rd Jan 2008. Drug Eluting Stents overhyped, overused and overpriced? . William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be. What did we expect from DES ?. Eliminate restenosis, at last . . .

619 views • 41 slides

Carlo Briguori, MD, FACC, FSCAI Clinica Mediterranea, Naples, Italy

NAPLES III N ovel A pproaches in P reventing or L imiting E vent III Tria L Randomised Comparison of Bivalirudin versus Unfractionated Heparin in Patients at High Risk of Bleeding Undergoing Elective Coronary Stenting thought the Femoral Approach.

459 views • 33 slides

Predictors of Acute, Subacute and Late Stent Thrombosis After Acute MI Primary Angioplasty in the Horizons AMI Trial

Predictors of Acute, Subacute and Late Stent Thrombosis After Acute MI Primary Angioplasty in the Horizons AMI Trial.

774 views • 28 slides

A Prospective, Randomized Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM T

A Prospective, Randomized Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial.

448 views • 26 slides

Angiographic Findings in Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial

Angiographic Findings in Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) Trial. Alexandra J. Lansky 1 , Ken Mori 1 , Ricardo A. Costa 1 , Michel Bertrand 2 , Frederick Feit 3 , Cordy Pietras 1 , Ecatarina Cristea 1 , Stuart Pocock 4 , Magnus Ohman 5 , Gregg W. Stone 1.

663 views • 24 slides

Stent Thrombosis Following Primary PCI in STEMI: Predictors, Clinical Impact and Preventive Strategies from the Horizons

Stent Thrombosis Following Primary PCI in STEMI: Predictors, Clinical Impact and Preventive Strategies from the Horizons AMI Trial. George D. Dangas, MD Columbia University Medical Center . Disclosures. Speaker honoraria Sanofi-Aventis, Astra Zeneca and BMS Not sponsors of this study

489 views • 24 slides

Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM Department of Emergency Medicine Pennsylvania Hospital, Philadelphia

OPTIMAL UPSTREAM ANTITHROMBIN THERAPY IN NSTE ACS PATIENTS MANAGED IN THE CARDIAC CATH LAB: DOES IT MATTER WHICH AGENT IS STARTED IN THE ED?. Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM Department of Emergency Medicine Pennsylvania Hospital, Philadelphia.

417 views • 24 slides

A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUI

Gregg W. Stone MD for the ACUITY Investigators. A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the ACUITY Trial. Disclosures. Gregg W. Stone Consultant to The Medicines Company and BMS Imaging

411 views • 22 slides

353 views • 22 slides

Background

Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding The HORIZONS-AMI Trial. Gregg W. Stone, Tim Clayton, Roxana Mehran, Efthymios N. Deliargyris, Jayne Prats, Stuart J. Pocock.

367 views • 22 slides

Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding

Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding. The HORIZONS-AMI Trial. Gregg W. Stone, Tim Clayton, Roxana Mehran, Efthymios N. Deliargyris, Jayne Prats, Stuart J. Pocock TCT 2012; JACC 2012;60(17SupplB):B16. Background.

331 views • 21 slides

Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center

Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center. Implications of Preoperative Thienopyridine Use Prior to Coronary Bypass Graft Surgery in Patients with ACS: A Report from the ACUITY Trial. Disclosures. Sanofi-aventis: Consultant, speaker

199 views • 19 slides

Sigmund Silber, MD, PhD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany

The MASTER Trial A Prospective , Randomized, Multicenter Evaluation of a PET Micronet Mesh Covered Stent (MGuard) in STEMI. Sigmund Silber, MD, PhD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany for the MASTER Investigators. Disclosures. Grant Support for the MASTER Trial.

252 views • 10 slides

Meta Analysis of Primary PCI trials

Meta Analysis of Primary PCI trials Andreas Baumbach*, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, and Gregg W. Stone.

190 views • 6 slides